Humacyte, Inc. (HUMA) Operating Margin
- Operating margin · 12 months: Value -5240.78%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -5240.78% | Operating income / revenue. Period ending 2026-06-30. $-111.16M ÷ $2.12M × 100 ≈ -5240.78% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -111.16M USD | Operating Income (Loss) |
| Revenue | 2.12M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 12.61M USD | Cost of Goods and Services Sold |
| Research and development | 69.48M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-111.16M | $2.12M | $12.61M | $69.48M | (m) | -5240.78% |
| 2026-03-31 | $-113.89M | $2.02M | $11.59M | $73.35M | (m) | -5649.21% |
| 2025-12-31 | $-108.14M | $2.04M | $9.70M | $69.30M | (m) | -5306.04% |
| 2025-09-30 | $-105.39M | (m) | (m) | $75.35M | (m) | (m) |
| 2025-06-30 | $-111.23M | (m) | (m) | $81.01M | (m) | (m) |
| 2025-03-31 | $-111.00M | (m) | (m) | $82.75M | (m) | (m) |
| 2024-12-31 | $-114.40M | (m) | (m) | $88.60M | (m) | (m) |
| 2024-09-30 | $-112.49M | (m) | (m) | $88.12M | (m) | (m) |
| 2024-06-30 | $-106.88M | (m) | (m) | $83.75M | (m) | (m) |
| 2024-03-31 | $-104.11M | (m) | (m) | $80.54M | (m) | (m) |
| 2023-12-31 | $-100.05M | (m) | (m) | $76.55M | (m) | (m) |
| 2023-09-30 | $-94.66M | (m) | (m) | $71.33M | (m) | (m) |
| 2023-06-30 | $-93.53M | (m) | (m) | $70.11M | (m) | (m) |
| 2023-03-31 | $-85.33M | (m) | (m) | $64.22M | (m) | (m) |
| 2022-12-31 | $-84.58M | (m) | (m) | $63.26M | (m) | (m) |
| 2022-09-30 | $-85.42M | (m) | (m) | $64.55M | (m) | (m) |
| 2022-06-30 | $-82.46M | (m) | (m) | $62.60M | (m) | (m) |
| 2022-03-31 | $-83.20M | (m) | (m) | $62.52M | (m) | (m) |
| 2021-12-31 | $-81.21M | (m) | (m) | $61.34M | (m) | (m) |
| 2021-09-30 | $-4.32M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-987.01K | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |